This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Mantle cell lymphoma (MCL)	CD37; DNA (cytosine-5-)-methyltransferase 1 (DNMT1); histone deacetylase (HDAC)	<p><i>In vitro</i> studies suggest that inhibiting hypermethylation of genes associated with MCL could help treat the cancer. In primary human MCL samples and cell lines overexpressing hypomethylated <i>CD37</i>, a <i>CD37</i> inhibitor reduced cell viability compared with no treatment. In three MCL cell lines, a DNMT1 inhibitor and an HDAC inhibitor increased the expression of four hypermethylated genes, resulting in greater apoptosis than that caused by either agent alone. Future studies could include testing DNMT1 and <i>CD37</i> inhibitors in animal models of MCL.</p> <p>Trubion Pharmaceuticals Inc. and Facet Biotech Corp.'s TRU-016, a humanized small modular immunopharmaceutical (SMIP) targeting <i>CD37</i>, is in Phase I/II testing to treat chronic lymphocytic leukemia (CLL).</p> <p>SuperGen Inc.'s SGI-110 (S110), a decitabine-derived DNMT1 inhibitor, is in preclinical testing to treat myelodysplastic syndrome (MDS), acute myelogenous leukemia (AML) and solid tumors.</p> <p>SciBX 3(22); doi:10.1038/scibx.2010.669 Published online June 3, 2010</p>	Patent and licensing status unavailable	<p>Leshchenko, V. <i>et al. Blood</i>; published online April 28, 2010; doi:10.1182/blood-2009-12-257485</p> <p>Contact: Samir Parekh, Albert Einstein College of Medicine of Yeshiva University, Bronx, N.Y. e-mail: samir.parekh@einstein.yu.edu</p>